GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Cyclically Adjusted PB Ratio

PTGX (Protagonist Therapeutics) Cyclically Adjusted PB Ratio : 8.83 (As of Jul. 06, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-07-06), Protagonist Therapeutics's current share price is $51.05. Protagonist Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $5.78. Protagonist Therapeutics's Cyclically Adjusted PB Ratio for today is 8.83.

The historical rank and industry rank for Protagonist Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

PTGX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.58   Med: 7.92   Max: 9.85
Current: 8.84

During the past years, Protagonist Therapeutics's highest Cyclically Adjusted PB Ratio was 9.85. The lowest was 6.58. And the median was 7.92.

PTGX's Cyclically Adjusted PB Ratio is ranked worse than
87.04% of 679 companies
in the Biotechnology industry
Industry Median: 1.58 vs PTGX: 8.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Protagonist Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $11.126. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.78 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Protagonist Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Protagonist Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Cyclically Adjusted PB Ratio Chart

Protagonist Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 6.95

Protagonist Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 8.61 6.95 8.37

Competitive Comparison of Protagonist Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Protagonist Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagonist Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Protagonist Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Protagonist Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=51.05/5.78
=8.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Protagonist Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=11.126/134.9266*134.9266
=11.126

Current CPI (Mar. 2025) = 134.9266.

Protagonist Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 -1.679 99.792 -2.270
201603 -2.388 100.470 -3.207
201606 -2.830 101.688 -3.755
201609 5.833 101.861 7.726
201612 5.236 101.863 6.936
201703 4.449 102.862 5.836
201706 3.611 103.349 4.714
201709 3.413 104.136 4.422
201712 5.720 104.011 7.420
201803 5.416 105.290 6.941
201806 5.074 106.317 6.439
201809 5.135 106.507 6.505
201812 4.853 105.998 6.177
201903 4.310 107.251 5.422
201906 3.377 108.070 4.216
201909 3.505 108.329 4.366
201912 2.938 108.420 3.656
202003 2.284 108.902 2.830
202006 4.551 108.767 5.646
202009 4.545 109.815 5.584
202012 6.392 109.897 7.848
202103 5.902 111.754 7.126
202106 7.521 114.631 8.853
202109 6.915 115.734 8.062
202112 6.272 117.630 7.194
202203 6.216 121.301 6.914
202206 5.504 125.017 5.940
202209 4.952 125.227 5.336
202212 4.370 125.222 4.709
202303 4.202 127.348 4.452
202306 5.115 128.729 5.361
202309 5.241 129.860 5.446
202312 5.834 129.419 6.082
202403 9.564 131.776 9.793
202406 9.212 132.554 9.377
202409 8.936 133.029 9.063
202412 11.064 133.157 11.211
202503 11.126 134.927 11.126

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Protagonist Therapeutics  (NAS:PTGX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Protagonist Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagonist Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Executives
Asif Ali officer: Chief Financial Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Patel Dinesh V Ph D director, officer: President and CEO C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta officer: Chief Development Officer 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd director 3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick director
Bryan Giraudo director 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu officer: Chief Scientific Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame officer: Chief Medical Officer C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035

Protagonist Therapeutics Headlines